Switzerland: VectivBio raises US$125m in underwritten share offer

Nasdaq-listed VectivBio Holding, a clinical-stage biopharmaceutical company, has priced an underwritten offering of 16,700,000 ordinary shares at US$7.50 per share, raising US$125m in gross proceeds. Investors agreeing to underwrite the offer include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, Forbion’s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital, TCG X,…

You must be a HMI Subscriber to view this content.

Subscribe Now »